Patients with MPNs, especially those with JAK2 mutations, are at increased risk of thrombotic events due to several mechanisms, including hyperviscosity, increased platelet activation, and endothelial dysfunction [4]. This evidence concerns the gene JAK2 and endothelial dysfunction.